Ligand-activated GPCRs enhance insulin secretion through mechanisms that are either dependent or independent of the blood glucose level (Oh and Olefsky, 2016), thus leading to condescending hyperinsulinemia and β-cell failure. Here, INS is linked to hyperinsulinism.